US First Amendment Defamation Lawsuit Dismissal Implications for Media Entities and Public Figure Litigation Risk EVLV Evolv shares rise nearly 25 percent even as fourth quarter 2025 earnings lag consensus analyst expectations STOK Stoke Therapeutics Q4 2025 EPS misses estimates by 333 pushing shares 258 lower in todays session